Beyond Air, Inc. (XAIR)
- Previous Close
0.2071 - Open
0.2000 - Bid 0.1470 x 200
- Ask 0.2601 x 200
- Day's Range
0.1990 - 0.2146 - 52 Week Range
0.1990 - 1.4850 - Volume
3,521,925 - Avg. Volume
1,776,703 - Market Cap (intraday)
18.539M - Beta (5Y Monthly) 0.16
- PE Ratio (TTM)
-- - EPS (TTM)
-1.0000 - Earnings Date Jun 23, 2025 - Jun 27, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
2.25
Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. It operates through two segments, Beyond Air and Beyond Cancer. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. In addition, the company develops ultra-high concentration NO in Phase 1 clinical trial to treat solid tumors. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.
www.beyondair.netRecent News: XAIR
View More
Performance Overview: XAIR
Trailing total returns as of 4/24/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: XAIR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: XAIR
View MoreValuation Measures
Market Cap
18.54M
Enterprise Value
9.60M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.79
Price/Book (mrq)
1.05
Enterprise Value/Revenue
3.17
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-72.62%
Return on Equity (ttm)
-262.69%
Revenue (ttm)
3.02M
Net Income Avi to Common (ttm)
-52.3M
Diluted EPS (ttm)
-1.0000
Balance Sheet and Cash Flow
Total Cash (mrq)
10.95M
Total Debt/Equity (mrq)
58.31%
Levered Free Cash Flow (ttm)
-30.04M
Research Analysis: XAIR
View MoreResearch Reports: XAIR
View MoreDaily – Vickers Top Buyers & Sellers for 12/20/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 08/30/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Insider Picks for 06/09/2023
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 06/08/2023
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.